Therefore, in a post hoc pilot study, we determined sPD-L1 levels in prospectively collected pretreatment and on-treatment serum samples of UTUC patients who underwent either surgical or systemic (CTX or ICI) treatment. This evidence concerns the gene SPDL1 and renal pelvis/ureter urothelial carcinoma.